Platelet Glycoprotein IIb/IIIa Inhibition with Coronary Stenting for Acute Myocardial Infarction
Top Cited Papers
Open Access
- 21 June 2001
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 344 (25) , 1895-1903
- https://doi.org/10.1056/nejm200106213442503
Abstract
When administered in conjunction with primary coronary stenting for the treatment of acute myocardial infarction, a platelet glycoprotein IIb/IIIa inhibitor may provide additional clinical benefit, but data on this combination therapy are limited.Keywords
This publication has 32 references indexed in Scilit:
- Coronary Angioplasty with or without Stent Implantation for Acute Myocardial InfarctionNew England Journal of Medicine, 1999
- Acute and nine-month clinical outcomes after “suboptimal” coronary stentingJournal of the American College of Cardiology, 1999
- Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary RevascularizationNew England Journal of Medicine, 1997
- A Randomized Comparison of Antiplatelet and Anticoagulant Therapy after the Placement of Coronary-Artery StentsNew England Journal of Medicine, 1996
- Effect of polarity on the success of transthoracic shocks in patients with atrial fibrillationJournal of the American College of Cardiology, 1996
- Ticlopidine and subcutaneous heparin as an alternative regimen following coronary stentingCatheterization and Cardiovascular Diagnosis, 1994
- Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six monthsThe Lancet, 1994
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994
- The Effects of Tissue Plasminogen Activator, Streptokinase, or Both on Coronary-Artery Patency, Ventricular Function, and Survival after Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinaseJournal of the American College of Cardiology, 1988